– UK, London – Proteome Sciences plc (LON: PRM) today announced that Dr. Mariola Söhngen has been appointed to its Board of Directors as CEO effective on September 15th, 2020.
“The Board is delighted to appoint Dr, Mariola Söhngen as our new CEO where she will build on the strong foundations that have already been established. Mariola’s time as Chief Medical Officer at Paion together with her international experience and network will bring major benefits to our business as we look to engage more broadly with new and existing clients in the US, Europe and to address the rapidly growing Asian markets.” said Board Chairman, Christopher Pearce.
Dr Ian Pike remains a director of the Company as CSO, having also fulfilled the role of Interim CEO until Dr Söhngen’s appointment.
About Dr. Mariola Söhngen
Dr. Söhngen has established a strong and successful career in the pharmaceutical industry both in the US and Europe. She was a co-founder of Paion AG which developed a clinical-stage asset for the treatment of stroke and subsequently delivered a novel anaesthetic that received FDA approval earlier this year. Dr. Söhngen was instrumental in the acquisition of UK listed CeNeS Pharmaceuticals plc by Paion AG. Dr. Söhngen has also held roles as CEO at Mologen AG and Convert Pharmaceuticals and most recently ran a pharmaceutical consultancy with a strong focus on supporting Chinese companies and investors trying to enter the European pharmaceuticals research and development market.
Dr. Söhngen said “I am very much looking forward to working with the highly respected and committed team at Proteome Sciences. The company has established a unique position in Precision Medicine through its specialist services business and the range of TMT and TMTpro chemical tags sold globally by Thermo Scientific. I am excited to work with the board to expand commercial activities and continue to develop the corporate strategy. From my involvement in stroke at Paion, I arrive at the company highly impressed with the quality of the Proteome Sciences’ technology, in particular, the biomarker discovery capabilities in Precision Medicine and Diagnostics which are of ever-increasing importance and value in these challenging times. As CEO of Proteome Sciences, I look forward to applying the broad experience gained from my previous interactions with a wide range of pharmaceutical companies to strengthen Proteome Sciences´ position in Precision Medicine and to drive shareholder value.”
About Proteome Sciences plc
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant and TMT MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.
For more information: https://www.proteomics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.